Retinal vein occlusions: A review for the internist

Internal and Emergency Medicine

Volumn 6, Issue 4, 2011, Pages 307-314

  Marcucci, Rossella ^a   Sofi, Francesco ^a   Grifoni, Elisa ^a   Sodi, Andrea ^a   Prisco, Domenico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Homocysteine; Retinal vein occlusion; Risk factors; Thrombophilia

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

FIBRINOLYSIS; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTERNAL MEDICINE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA VEIN; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR;

FIBRINOLYSIS; FLUORESCEIN ANGIOGRAPHY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNAL MEDICINE; RETINAL VEIN; RETINAL VEIN OCCLUSION; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 79960563636     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0478-2     Document Type: Review

References (50)

1. Prisco D, Marcucci R, Bertini L, Gori AM (2002) Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med 13: 163-169.
2. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P (2001) Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 131: 61-77.
3. Hayreh SS, Zimmermann MG, Podhajsky P (1994) Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Opthalmol 117: 429-441.
4. Williamson T (1997) Central retinal vein occlusion: what's the story? Br J Ophthalmol 81: 698-704.
5. The Central Vein Occlusion Study Group (1993) Baseline and early natural history report. Arch Ophthalmol 111: 1087-1095.
6. The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115: 486-491.
7. Cole MD, Dodson PM, Hendeles S (1989) Medical conditions underlying retinal vein occlusion in patients with glaucoma or ocular hypertension. Br J Ophthalmol 73: 693-698.
8. Fong ACO, Schatz H, McDonald HR (1992) Central retinal vein occlusion in young adults (papillophlebitis). Retina 12: 3-11.
9. The Eye disease case-control study group (1996) Risk factors for branch retinal vein occlusion. Am J Ophthalmol 116: 286-296.
10. The Eye disease case control study group (1996) Risk factors for central retinal vein occlusion. Arch Ophthalmol 114: 545-554.
11. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountain Eye study. Arch Ophthalmol 114: 1243-1247.
12. Dodson PM, Kritzinger EE (1985) Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion. Trans Ophthalmol Soc UK 104: 114-119.
13. Prisco D, Marcucci R (2002) Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 32: 308-311.
14. Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, Poli D, Pepe G, Abbate R, Prisco D (2001) Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 86: 772-776.
15. Bandello F, Viganòd'Angelo S, Parlavecchia M et al (1994) Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost 72: 39-43.
16. Graham SL, Goldberg L, Murray B, Beaumont P, Chong BH (1996) Activated protein C resistance: low incidence in glaucomatous disc hemorrhage and central retinal vein occlusion. Aust N Z Ophthalmol 24: 199-205.
17. Salomon O, Moisseiev J, Rosenberg N (1998) Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis 9: 617-622.
18. Linna T, Ylikorkay A, Kontula K, Puska P, Tervo T (1997) Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 77: 212-216.
19. Albisinni R, Coppola A, Loffredo M, Cerbone AM, Di Minno G, Greco GM (1998) Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 80: 702-703.
20. Glueck CJ, Bell H, Vadlamani L, Heritable thrombophilia, hypofibrinolysis (1999) Possible causes of retinal vein occlusion. Arch Ophthalmol 117: 43-49.
21. Janssen MCH, den Heijer M, Cruysberg JRM, Wollersheim H, Bredie SJH (2005) Retinal vein occlusion: a form of venous thrombosis or a complications of atherosclerosis? Thromb Haemost 93: 1021-1026.
22. McGimpsey SJ, Woodside JV, Cardwell C, Cahill M, Chakravarthy U (2009) Homocysteine, methylenetetrahydrofolatereductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 116: 1778-1787.
23. Sodi A, Giambene B, Marcucci R, Sofi F, Bolli P, Abbate R, Prisco D, Menchini U (2008) Atherosclerotic and thrombophilic risk factors in patients with recurrent central retinal vein occlusion. Eur J Ophthalmol 18: 233-238.
24. Gori AM, Sofi F, Corsi AM et al (2006) Predictors of vitamin B6 and folate concentrations in older persons: the INCHIANTI study. Clin Chem 52: 1318-1324.
25. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg I (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270: 2693-2698.
26. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM (2001) Low plasma levels of vitamin B6 are independently associated with a heightened risk of deep vein thrombosis. Circulation 104: 2442-2446.
27. Rimm EB, Willett WC, Hu FB (1998) Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 279: 359-364.
28. Terrazzi P, DI Micco P, Quaglia I (2005) Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B12 in patients with retinal vein occlusion. Thromb J 3: 13-15.
29. Sofi F, Marcucci R, Bolli P, Giambene B, Sodi A, Fedi S, Menchini U, Gensini GF, Abbate R, Prisco D (2008) Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis 198: 223-227.
30. Schoene NW, Chanmugam P, Reynolds RD (1986) Effect of oral vitamin B6 supplementation on in vitro platelet aggregation. Am J ClinNutr 43: 825-830.
31. Meydani SN, Hayek M, Coleman L (1992) Influence of vitamins E and B6 on immune response. Ann N Y Acad Sci 669: 125-139.
32. Gori AM, Marcucci R, Fatini C, Gensini F, Sticchi E, Sodi A, Cappelli S, Menchini U, Gensini GF, Abbate R, Prisco D (2004) Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 92: 54-60.
33. Sofi F, Marcucci R, Fedi S, Giambene B, Sodi A, Menchini U, Gensini GF, Abbate R, Prisco D (2009) High lipoprotein(a) are associated with an increased risk of retinal vein occlusion. Atherosclerosis. doi: 10. 1016/j. atherosclerosis. 2009. 11. 006.
34. Carbone J, Sanchez-Ramon S, Cobo-Soriano R, Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders (2001) Comparison with ocular inflammatory diseases. J Rheumatol 28: 2437-2441.
35. Sofi F, Mannini L, Marcucci R, Bolli P, Sodi A, Giambene B, Menchini U, Gensini GF, Abbate R, Prisco D (2007) Role of haemorheological factors in patients with retinal vein occlusion. Thromb Haemost 98: 1215-1219.
36. Hansen LL, Wiek J, Wiederholt M (1989) A randomised prospective study of treatment of non-ischemic central retinal vein occlusion by isovolaemic hemodilution. Br J Ophthalmol 73: 895-899.
37. Houtsmuller AJ, Vermeulen JA, Klompe M (1984) The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 15: 219-229.
38. Muravyov AV, Yakusevich VV, Surovaya L (2004) The effect of simvastatin therapy on hemorheological profile in coronary heart disease patients. Clin Hemorheol Microcirc 31: 251-256.
39. Martin SC, Butcher A, Martin N (2002) Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol 86: 774-776.
40. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BEK, Wong TY, Mitchell P (2007) Retinal vein occlusion and vascular mortality. Ophthalmology 114: 520-524.
41. Hu CC, Ho JD, Lin HC (2009) Retinal vein occlusion and the risk of acute myocardial infarction: a 3-year follow-up study. Br J Ophthalmol 93: 717-720.
42. Ho JD, Liou SW, Lin HC (2009) Retinal vein occlusion and the risk of stroke development: a five year follow-up study. Am J Ophthalmol 147: 283-290.
43. Di Capua M, Coppola A, Albissini R, Tufano A, Guida A, Di Minno MND, Cirillo F, Loffredo M, Cerbone AM (2009) Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis. doi: 10. 1007/s11239-009-0388-1.
44. Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W (2010) Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 103: 271-276.
45. Ageno W, Cattaneo R, Manfredi E, Chelazzi P, Venco L, Ghiraduzzi A, Cimino L, Filippucci E, Ricci AL, Romanelli D, Incorvaia C, D'Angelo S, Campana F, Molfino F, Scannapieco G, Rubbi F, Imberti D (2010) Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double bind, controlled study. Thromb Res. doi: 10. 1016/j. thromres. 2009. 05. 007.
46. Farahvash MS, Moghaddam MM, Moghimi S et al (2008) Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol 43: 79-83.
47. Farahvash MS, Moradimogadam M, Farahvash MM et al (2008) Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med 11: 418-422.
48. Kohner EM, Pettit JE, Hamilton AM (1976) Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J 1: 550-553.
49. Hattenbach LO, Friedrich AC, Lerche R (2009) Retinal vein occlusion and low-dose fibrinolytic therapy: a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 29: 932-940.
50. Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ (2010) Low molecular weigh heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica. doi: 10. 3324/haematol. 2010. 023614.